{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:08Z","timestamp":1790806628582,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106567"],"award-info":[{"award-number":["JP20ck0106567"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ck0106297"],"award-info":[{"award-number":["JP17ck0106297"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108249","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:36:32Z","timestamp":1783712192000},"page":"108249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-human phase I study of hypoxia-targeting 64Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64)"],"prefix":"10.1016","volume":"11","author":[{"given":"H.","family":"Kurihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-6767","authenticated-orcid":false,"given":"K.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Miyakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-1993","authenticated-orcid":false,"given":"M.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.T.","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sadachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Waki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-R.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-678X","authenticated-orcid":false,"given":"K.","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-9148","authenticated-orcid":false,"given":"M.","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-0281","authenticated-orcid":false,"given":"H.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108249_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.108249_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma\u2014are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib4","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782043","article-title":"Hypoxia contributes to poor prognosis in primary IDH-wt GBM by inducing tumor cells MES-like transformation trend and inhibiting immune cells activity","volume":"11","author":"Xiong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41571-021-00539-4","article-title":"Therapeutic targeting of the hypoxic tumour microenvironment","volume":"18","author":"Singleton","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1073\/pnas.98.3.1206","article-title":"Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy","volume":"98","author":"Lewis","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2026.108249_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02988502","article-title":"Retention mechanism of hypoxia selective nuclear imaging\/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells","volume":"15","author":"Obata","year":"2001","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nucmedbio.2004.08.012","article-title":"Basic characterization of 64Cu-ATSM as a radiotherapy agent","volume":"32","author":"Obata","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.esmoop.2026.108249_bib10","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1088\/0031-9155\/54\/7\/017","article-title":"In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals","volume":"54","author":"Holland","year":"2009","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.esmoop.2026.108249_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nucmedbio.2011.08.008","article-title":"Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less \u03c10 cells and cybrids carrying MELAS mitochondrial DNA mutation","volume":"39","author":"Yoshii","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.esmoop.2026.108249_bib12","first-page":"1155","article-title":"Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3174\/ajnr.A3159","article-title":"Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma","volume":"34","author":"Tateishi","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.esmoop.2026.108249_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12149-018-1241-4","article-title":"Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET\/CT in patients with glioma","volume":"32","author":"Toriihara","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nucmedbio.2010.08.009","article-title":"Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma","volume":"38","author":"Yoshii","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.esmoop.2026.108249_bib16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jrr\/rrv042","article-title":"Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission","volume":"56","author":"McMillan","year":"2015","journal-title":"J Radiat Res"},{"key":"10.1016\/j.esmoop.2026.108249_bib17","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3390\/cancers12103022","article-title":"Carbon ion radiobiology","volume":"12","author":"Tinganelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108249_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tranon.2017.10.006","article-title":"Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts","volume":"11","author":"Yoshii","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib19","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib20","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1093\/neuonc\/noae125","article-title":"Targeted radionuclide therapy for gliomas: emerging clinical trial landscape","volume":"26","author":"Weller","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s13311-016-0504-9","article-title":"The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu","volume":"14","author":"Huuskonen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.esmoop.2026.108249_bib22","series-title":"WHO Classification of Tumours. rev 4th ed. Vol 1","article-title":"WHO classification of tumours of the central nervous system","year":"2016"},{"key":"10.1016\/j.esmoop.2026.108249_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10967-019-06738-9","article-title":"Process development of [64Cu]Cu-ATSM: efficient stabilization and sterilization for therapeutic applications","volume":"322","author":"Matsumoto","year":"2019","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.esmoop.2026.108249_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108249_bib25","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jjco\/hys121","article-title":"Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma","volume":"42","author":"Nagane","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib27","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib28","unstructured":"Ferlay J, Em LF, Laversanne M, et al. Global Cancer Observatory: Cancer Today. version 1.1. International Agency for Research on Cancer. Available at https:\/\/gco.iarc.who.int\/today. Accessed October 14, 2025."},{"key":"10.1016\/j.esmoop.2026.108249_bib29","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108249_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12883-024-03954-z","article-title":"Re-irradiation for recurrent glioblastoma: a pattern of care analysis","volume":"24","author":"Rogers","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.esmoop.2026.108249_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10143-024-03087-4","article-title":"Prevalence, prognostic and clinicopathological value of HIF-1\u03b1 in glioblastoma patients: a systematic review and meta-analysis","volume":"47","author":"Li","year":"2024","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.esmoop.2026.108249_bib32","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1038\/s41467-020-20144-w","article-title":"HIF1A signaling selectively supports proliferation of breast cancer in the brain","volume":"11","author":"Ebright","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108249_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2967\/jnumed.108.051326","article-title":"An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix","volume":"49","author":"Lewis","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.esmoop.2026.108249_bib34","series-title":"WHO Classification of Tumours","article-title":"Central nervous system tumours","year":"2021"},{"key":"10.1016\/j.esmoop.2026.108249_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jjco\/hyaf026","article-title":"Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial","volume":"55","author":"Ando","year":"2025","journal-title":"Jpn J Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:33:15Z","timestamp":1787848395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926021915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926021915"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108249","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human phase I study of hypoxia-targeting 64Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108249"}}